Sunflower Mannose binding Lectin-Associated Serine Protease Inhibitor-1 (SFMI-1) and -2: Significant Inhibitors of Mannose binding Lectin Pathway which Helps in Multiple Sclerosis Treatment

Pouya Ghaderi*, Hamed Delfaraz, Mohaddese Ahmadabadi, Mahdiye Ehsani

Islamic Azad University, Mashhad Branch, Mashhad, Iran

Abstract

One of the important parts of innate immunity is complement system that occurs in three different ways; the classic, the alternative and the lectin pathway. The four pattern recognition molecules that have been identified till now are Mannose binding lectin (MBL), a component of lectin pathway, and three ficolins (ficolin1,-2 and -3) which compound to the carbohydrates of the cell surface. MBL associated serine protease1 (MASP-1), MASP-2 and -3 are three proteases which associate with recognition molecules. Also MBL-associated protein 19 and MBL-associated protein 44 are two non-catalytic molecules that their role is association with recognition molecules. MASP-1 and MASP-2 activate the lectin pathway but function of MASP-3 is unclear. Although some researches show that MASP-3 down regulates activation of two other MASPs and has a similar role like MBL-association 19 and MBL-association 44 that they inhibit MBL pathway too. Researches show that MBL pathway has a critical role in pathogenesis of autoimmune diseases such as multiple sclerosis (MS). Researches indicate that levels of MBL pathway activator components (MASP-1 and MASP-2) are higher in serum plasma of MS patients. Inhibiting activators of MBL pathway seems to be useful for MS treatment and reducing its disabilities. Sunflower MASP inhibitor-1 (SFMI-1) and sunflower MASP inhibitor-2 (SFMI-2) are two peptides with 14 amino acids that inhibit MASP-1 and MASP-2 and block the lectin pathway activation. This article suggests using SFMI-1 and SFMI-2 in drugs to targeted therapy of MS and decreasing its symptoms.

Keywords: Mannose-binding lectin, Mannose-binding lectin-associated serine protease (MASP), Multiple sclerosis

*Corresponding Author: Pouya Ghaderi
  Email: pouyaghaderi73@gmail.com